Study VEG108844, a Study of Pazopanib versus Sunitinib in the Treatment of Subjects with Locally Advanced and/or Metastatic Renal Cell Carcinoma

Trial Profile

Study VEG108844, a Study of Pazopanib versus Sunitinib in the Treatment of Subjects with Locally Advanced and/or Metastatic Renal Cell Carcinoma

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 04 Jul 2017

At a glance

  • Drugs Pazopanib (Primary) ; Sunitinib
  • Indications Renal cell carcinoma
  • Focus Registrational; Therapeutic Use
  • Acronyms COMPARZ
  • Sponsors GlaxoSmithKline; Novartis; Novartis Pharmaceuticals
  • Most Recent Events

    • 06 Jun 2017 Results of exploratory subanalysis presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 06 Jun 2017 Results assessing the relationship between dosing, safety, and efficacy in pazopanib (PAZ) and sunitinib (SUN) treated patients who did or did not undergo dose reduction or interruption resulting from adverse events (AEs) and other reasons presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top